FDA Working To Fill Advisory Panel Vacancies While Tightening Conflict-Of-Interest Rules
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA is working on an initiative to fill many of the current vacancies on its advisory committees, but it is not backing down from a strict conflict-of-interest policy that many see as contributing to the advisory panel vacancies
You may also be interested in...
FDA Transparency Initiative Sees No Clear Path To Releasing Documents, Woodcock Indicates
FDA is finding the possible release of its voluminous documents one of the more challenging aspects of the effort to make its operations and decisions more open to the public, and the challenges are both in policies and resources, FDA's Janet Woodcock says
FDA Transparency Initiative Sees No Clear Path To Releasing Documents, Woodcock Indicates
FDA is finding the possible release of its voluminous documents one of the more challenging aspects of the effort to make its operations and decisions more open to the public, and the challenges are both in policies and resources, FDA's Janet Woodcock says
Going Back to a New Approach: FDA, Outside Experts, and Conflicts of Interest
FDA has gone far-maybe too far-in excluding outside experts from advisory committee panels who have potential conflicts of interest. The agency is considering easing back the restrictions. What will it mean for future external guidance to FDA?